Oxurion Announces Extraordinary General Shareholders' Meeting
Leuven, BELGIUM - June 4, 2024 - 07:00 PM CET - Oxurion NV (https://oxurion.com/) (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces an extraordinary general shareholders' meeting to be held on Thursday July 4, 2024 at 11:00 AM (CET).
This extraordinary general shareholders' meeting regards the proposal of share consolidation in respect of all outstanding shares of the Company by means of a 1-for-10,000 share consolidation.
The convening notice and other documents pertaining to the shareholders' meeting, can be consulted on Oxurion's website Oxurion/shareholders (https://ir.oxurion.com/shareholder-information/shareholder-meeting).
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com (http://www.oxurion.com).
Please contact for additional information:
+-------------------------------------+----------------------------------------+
|Oxurion NV |Backstage Communication | |Pascal Ghoson |Jurgen Vluijmans | |Chief Executive Officer |Partner | |pascal.ghoson@oxurion.com |jurgen@backstagecom.be | |(mailto:pascal.ghoson@oxurion.com) |(mailto:jurgen@backstagecom.be) | | | | +-------------------------------------+----------------------------------------+Â